• Financial Inclusion Accelerated

    Financial Inclusion Accelerated

    A new report from Kapronasia and Vocalink looks at how real-time payments are impacting financial inclusion around the world and what lies ahead.
  • Cross Border Payments in Asia

    Cross Border Payments in Asia

    Asia's cross border payments market is starting to heat up as countries overcome geographic, political, and cultural differences to develop sub-regional payment networks.
  • The Case for a Central Bank Digital Currency

    The Case for a Central Bank Digital Currency

    The concept of a Central Bank Digital Currency (CBDC) may seem far fetched, but not as far off as you might think.
  • 1
  • 2
  • 3

Latest Reports

Despite all of the hype around blockchain and cryptocurrency, the most impact will come from whether or not national governments will shift to a Central Bank Digital Currency (CBDC). A new report looks at the opportunities and challenges as well as the stark implications for citizens.
Most of the research into real-time payments has focused on potential new revenue streams and business models for banks to serve traditional retail and commercial customers. Although this research is valuable, it overlooks an essential segment of the population: the underbanked and financially excluded. Until now.
2017 was a year of significant interest into blockchain, the technology behind Bitcoin, and its application in China’s financial industry. Has the reality finally matched the hype or is the adoption of blockchain still lagging? What are the key user cases that are emerging and is it necessary for users to replace traditional technology with the new blockchain technology?


March 21, 2018 - Mar 22, 2018
Payments Summit 2018 - Helsinki
March 27, 2018 - Mar 28, 2018
MoneyLive: Digital Banking APAC 2018
May 03, 2018 - May 04, 2018
Seamless Asia Singapore
June 04, 2018 - Jun 06, 2018
Money 20/20 Europe - Amsterdam
June 08, 2018
Nanjing NEXT - Amcham
September 19, 2018 - Sep 20, 2018
Global Payments Summit KL
October 22, 2018 - Oct 23, 2018
Sibos Sydney
November 14, 2018 - Nov 16, 2018
Money 2020 China

Kapronasia is a leading provider of financial industry market research and consulting covering fintech, payments, banking, capital markets and blockchain.


Research From our offices across the region, we provide clients with the key insight and research they need to understand the market trends and challenges. Our research reports are used by numerous clients across the globe to make better business decisions about their Asia strategy.


Consulting We work closely with clients to better understand their business challenges and find lasting and value creating solutions. We have worked with some of the financial industry's largest players to help them re-define their business and drive growth.

A quick note on the GlaxoSmithKline inquiry in China

Written by Zennon Kapron 25 Jul 2013 25 Jul 2013

Although it's completely outside of our area of focus (beyond being China related), we have been getting a number of questions from clients and Kapronasia followers about the situation at GlaxoSmithKline (GSK) and so I thought we should give a bit of background, our position, and the relevance to China's FSI. 


If you haven't been following the news, very briefly, the Chinese government has accused GSK of bribing doctors and hospitals to take their products in exchange for trips and cash incentives allegedly facilitated by a local travel company. Shocker...  Some thoughts:

Firstly, this practice is growing increasingly rare, but is not-unheard of. In China, multinationals for years have operated through middlemen to, for lack of a better word, bribe local authorities, regulators and potential customers. Whether the intermediary was a marketing company, travel agent, or consultant, the agent would give the MNC a bit of arm's length to conduct business in what was once the only way of doing business in China.

Secondly, I find it very hard to believe that senior management outside of China did not know that this was happening. Bribes are rife in the pharma industry throughout the world and China has been known to be corrupt. If you can seriously say that you had no idea it was happening, you should be in a different job. To say that you/the company don't condone it, ok, not aware of it, impossible - don't throw your people under the bus and claim ignorance.

Thirdly, this is part of a Chinese government crackdown on corruption in China that is unlikely to abate anytime soon. If you are operating somehow illegally here, this is a sign that you need to change and change soon as both national and global companies are being monitored and investigated.

Finally, that vigilance is not limited to the pharma industry. Having been involved in the financial technology space here in China for nearly 10 years, we have seen graft and corruption. Whether it's revenue smoothing, over-inflated expenses or R&D centre visits ('really, you do your R&D in the Maldives??'), it has and does happen.

However, it is changing. Relationships are still going to be important. You need to be trusted to do business here, but don't get relationships confused with corruption. Will a $75 bottle of wine from California that you brought over be appreciated by a potential client? Yes of course, and it will help develop that relationship as it would with any other friend or acquaintance.

And you should think about it from that perspective: would you pay for a friend to go to London so that he would be a better friend? Well I suppose you could, but I would guess that's not a very deep friendship based on mutual trust. Much better to spend the time to get to know the client, show your commitment, and as trite as it sounds, become a 'trusted advisor'. Reasonable gifts do have their place as they do in any relationship. 

In a very brief conclusion, China is not an easy place to do business, but it is an important place to do business and you need to come in with your eyes open. Awareness is key. Complicity is not. 


Kapronasia Newsletter

Sign up for our email list and stay up to date with our latest insights.